<DOC>
	<DOCNO>NCT00001911</DOCNO>
	<brief_summary>This study test safety effectiveness drug call interleukin-12 ( IL-12 ) fight severe infectious ( tuberculosis ) cause group bacteria call mycobacteria . IL-12 similar substance body produce naturally strengthen immune function ( infection-fighting ability ) . It work stimulate white blood cell increase production chemical call interferon gamma , improve cure mycobacterial infection patient . In previous study , IL-12 improve immune function mycobacteria test tube experiment mouse . A recent study three patient mycobacterial infection treat drug show encouraging result . The drug also study extensively patient cancer , HIV infection hepatitis C. Patients study receive IL-12 injection skin twice week one year . They teach self-administer drug , home care nurse physician may also give injection . The drug dosage increase week determine safest effective dose fight infection . If intolerable side effect develop certain dose , previous dose level use next injection . That dose use rest study , unless unacceptable side effect develop level , case dose lower . Patients receive antibiotic mycobacteria . Physical examination blood urine test do month least first year every 3 month follow year evaluate kidney , liver , immune function . The first evaluation-at start study-is do inpatient basis .</brief_summary>
	<brief_title>Interleukin-12 Treatment Severe Nontuberculous Mycobacterial Infections</brief_title>
	<detailed_description>Severe nontuberculous mycobacterial infection patient infect HIV show due abnormality pathways generate use interferon gamma ( IFN gamma ) . In patient treatment IFN gamma effective improve cure infection . Recently , interleukin-12 ( IL-12 ) show potent inducer IFN gamma along cytokine . Experiments animal preliminary experience u human suggest IL-12 may important adjunct antimycobacterial therapy . We seek use IL-12 phase I/II trial treatment severe nontuberculous mycobacterial infection patient cure best tolerate conventional therapy IFN gamma . Patients study inborn acquire immune defect well IL-12 responsiveness vitro protocol 93-I-0119 `` Detection Characterization Host Defense Defects '' . Patients receive IL-12 subcutaneously 2 time weekly . We use intrapatient dose escalation protocol range 20 ng/kg 300 ng/kg , depend high dose tolerate patient . We expect study yield valuable information tolerance toxicity . We seek treat 10 patient next 3 year .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium Infections , Nontuberculous</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>Severe disseminate pulmonary nontuberculous mycobacterial infection refractory best tolerated conventional therapy addition IFN gamma deliver least 3 month . This infection must prove culture point illness . At time enrollment , patient eligible negative culture histopathologic , examinable , radiographic evidence ongoing infection . In vitro responsiveness IL12 demonstrate augmentation peripheral blood mononuclear cell ( PBMC ) phytohemagglutinin ( PHA ) induce IFN gamma production . Women childbearing age must negative pregnancy test ( urine serum ) time start study agree take measure avoid pregnancy throughout study receive IL12 . Males advise effect IL12 sperm wellknown , avoid conception study period . Age 18 year . Adequate hematopoietic , renal hepatic function , define : Absolute neutrophil count great equal 1000/microL ( GCSF permit ) ; Hemoglobin great equal 9 g/dl ( transfusion erythropoietin permit ) ; Platelet count great equal 100,000/microL ; Creatinine le equal 1.5 X upper limit normal ; Bilirubin le equal 1.5 X upper limit normal ; AST/SGOT le equal 2.5 X upper limit normal ; ALT/SGPT le equal 2.5 X upper limit normal ; Calculated Creatinine Clearance great 60 mL/min . Karnofsky Performance Status index great equal 70 . Written sign informed consent . No HIV infection . No active malignancy . No symptomatic cardiac disease ongoing treatment . No active seizure disorder ongoing treatment . No pregnancy lactation . No surgery two week prior start IL12 . No concurrent use systematic corticosteroid , except physiologic replacement . No exposure investigational drug within four week prior start dose . No gastrointestinal bleeding uncontrolled peptic ulcer disease . No history inflammatory bowel disease autoimmune disease rheumatoid arthritis systemic lupus erythematosus . No major illness , investigator 's judgement , substantially increase risk associate patient 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2003</verification_date>
	<keyword>Cytokine</keyword>
	<keyword>Interferon Gamma</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Disseminated</keyword>
	<keyword>Refractory</keyword>
	<keyword>Mycobacterial Infection</keyword>
	<keyword>Nontuberculosis Mycobacterial Infection</keyword>
	<keyword>Pulmonary Nontuberculous Mycobacterial Infection</keyword>
</DOC>